Drug Profile
PG 2
Alternative Names: Injectable astragalus polysaccharide; PG2; PHN011; PHN012; PHN013; PHN014; PHN015; Polysaccharides of Astragalus membranaceus; XueBaoLatest Information Update: 03 Jul 2023
Price :
$50
*
At a glance
- Originator Pharmagenesis
- Developer Pharmagenesis; PhytoHealth
- Class Phytotherapies; Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Fatigue; Leucopenia
- Phase II Stroke
- No development reported Idiopathic thrombocytopenic purpura
Most Recent Events
- 02 Jun 2023 Efficacy data from a phase II trial in Fatigue presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 27 Aug 2021 PhytoHealth Corporation completes a phase II trial in Fatigue in Taiwan (IV) (NCT03314805)
- 01 Mar 2018 PhytoHealth Corporation initiates a phase II trial in Fatigue in Taiwan (IV) (NCT03314805)